Prevents pregnancy. ANDA 201584, held by Lupin. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 201584 (Blisovi Fe 1/20), held by Lupin, was first approved by FDA on Nov 18, 2015, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Blisovi Fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Blisovi Fe 1/200.02MG;1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Aug 31, 2020 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 31, 2020 | Supplement 16Manufacturing | Approved | None posted |
| Sep 26, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 26, 2018 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| Nov 18, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters